Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Quantum Biopharma ( (TSE:QNTM) ) has issued an update.
On April 1, 2026, Quantum BioPharma announced it had formally submitted an Investigational New Drug application to the U.S. Food and Drug Administration for Lucid-21-302 (Lucid-MS), its multiple sclerosis candidate targeting demyelination, to support a planned Phase 2 trial. The filing follows completed Phase 1 studies showing Lucid-MS was safe and well tolerated, and, if cleared, the company aims to launch the Phase 2 study in the second quarter of 2026 with interim data projected for the fourth quarter.
Lucid-MS’s neuroprotective focus on inhibiting demyelination offers a differentiated approach in the fast-growing MS market, which management cites as a multibillion-dollar opportunity driven by rising diagnosis and demand for disease-modifying therapies. The IND milestone strengthens Quantum BioPharma’s clinical pipeline and strategic positioning in neurology while fitting into its broader model that pairs high-value drug development with recurring revenue from consumer health and strategic investments to support operations and limit shareholder dilution.
More about Quantum Biopharma
Quantum BioPharma Ltd. is a Toronto-based biopharmaceutical company focused on developing innovative assets and biotech solutions for neurodegenerative and metabolic disorders and alcohol misuse. Its lead program is Lucid-MS, a patented new chemical entity aimed at preventing and reversing myelin degradation in multiple sclerosis, alongside consumer health product UNBUZZD, which it invented and partially spun out while retaining royalties and certain pharma rights.
Through wholly owned subsidiary Lucid Psycheceuticals Inc., the company advances Lucid-MS through clinical development, targeting the global multiple sclerosis market. Quantum BioPharma also pursues revenue diversification via a 7% royalty stream from OTC unbuzzd sales up to a defined cap and maintains strategic digital-asset investments through FSD Strategic Investments Inc., supporting its growth and R&D funding model.
Average Trading Volume: 13,627
Technical Sentiment Signal: Sell
Current Market Cap: C$27.38M
For a thorough assessment of QNTM stock, go to TipRanks’ Stock Analysis page.